Home / Advanced Search

  • Title/Keywords

  • Author/Affliations

  • Journal

  • Article Type

  • Start Year

  • End Year

Update SearchingClear
  • Articles
  • Online
Search Results (2)
  • Open Access


    Surgery Combined with Molecular Targeted Therapy Successfully Treated Giant Esophageal Gastrointestinal Stromal Tumor

    Mengjie Li1,#, Jun Wei2,#, Guihua Xu3,#, Ying Liu3,*, Jian Zhu3,*

    Oncologie, Vol.24, No.2, pp. 349-356, 2022, DOI:10.32604/oncologie.2022.022436

    Abstract Gastrointestinal stromal tumors (GISTs) are rare neoplasms arising from mesenchymal cells of the digestive tract and abdomen. Only a few isolated cases of giant esophageal GISTs (greater than 5 cm in size) have been reported with clinical features and surgical methods. Radical esophagectomy with negative margins, followed by gastric tube reconstruction, is recommended for giant esophageal GISTs. However, patients undergoing this type of surgery experienced a sharp decrease in food intake (due to the removal of most of the stomach) and were prone to eating regurgitation, resulting in poor quality of life. We describe the… More >

  • Open Access


    Efficacy Evaluation of Imatinib for the Treatment of Melanoma: Evidence From a Retrospective Study

    Xiaoting Wei, Lili Mao, Zhihong Chi, Xinan Sheng, Chuanliang Cui, Yan Kong, Jie Dai, Xuan Wang, Siming Li, Bixia Tang, Bin Lian, Xieqiao Yan, Xue Bai, Li Zhou, Jun Guo, Lu Si

    Oncology Research, Vol.27, No.4, pp. 495-501, 2019, DOI:10.3727/096504018X15331163433914

    Abstract Melanoma is an aggressive malignancy with a poor prognosis. Current studies show that imatinib treatment is a promising approach in treating advanced melanoma patients harboring c-Kit mutations or amplifications. We retrospectively analyzed the clinical medical records of 78 patients with metastatic melanoma harboring c-Kit mutations or amplifications. These patients were treated with imatinib at a dose of 400 mg/day continuously unless intolerable toxicities or disease progression occurred. Endpoints for exploration included overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and disease of control rate (DCR). The median OS and PFS of all patients were More >

Displaying 1-10 on page 1 of 2. Per Page